# China Brucellosis Market

> China Brucellosis Market Research Report: Size, Share, Trend Analysis By Species (Brucella suis, Brucella abortus, Brucella melitensis, Brucella canis, others), By End-User (hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies, others), By Diagnosis (serological tests, molecular techniques, bone marrow biopsy, X-rays, computerized tomography (CT), magnetic resonance imaging (MRI), cerebrospinal fluid culture, echocardiography, others), By Treatment (antibiotics, vaccines, others), By Region - Forecast to 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 6.28%
- **2024:** $ 49.32 Million
- **2025:** $ 53.3 Million
- **2035:** $ 96.38 Million
- **Key Players:** China Animal Health and Epidemiology Center (CN), China National Pharmaceutical Group Corporation (CN), Hubei Huanong Animal Health Products Co Ltd (CN), Zhejiang Sijiqing Animal Pharmaceutical Co Ltd (CN), Shenzhen Huitong Pharmaceutical Co Ltd (CN), Guangdong Huanan Animal Health Products Co Ltd (CN), Beijing Huaduo Animal Health Technology Co Ltd (CN), Jiangsu Yurun Group Co Ltd (CN)

**Report ID:** MRFR/LS/51836-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/china-brucellosis-market-53597

---

## Market Summary

## **China Brucellosis Market Overview**

As per MRFR analysis, the China Brucellosis Market Size was estimated at 21.35 (USD Million) in 2023.The China Brucellosis Market is expected to grow from 23.25(USD Million) in 2024 to 77.17 (USD Million) by 2035. The China Brucellosis Market CAGR (growth rate) is expected to be around 11.523% during the forecast period (2025 - 2035).

**Key China Brucellosis Market Trends Highlighted**

The rising prevalence of brucellosis in livestock and rising consumer awareness of food safety are the main factors propelling the market in China. In rural and pastoral areas, where cattle production plays a major role in the economy, brucellosis is particularly common.

Government efforts to manage the disease through vaccination campaigns, information campaigns, and more stringent regulations have increased as a result. Recognizing the effects on public health, the Chinese government has put strategic measures into place to lower the infection rate and stop outbreaks, highlighting the significance of managing brucellosis in livestock.

This market has a lot of untapped potential, especially for the creation of locally relevant diagnostic instruments and efficient vaccines. Biotechnology research and development can result in novel products that improve animal health overall and disease control in particular.

A favorable climate exists for private companies to enter the market with innovative solutions that complement national health initiatives as the government makes investments in veterinary public health and animal disease prevention.

Government agencies and commercial businesses are increasingly working together to improve illness reporting and surveillance systems, according to recent trends. Strong monitoring and control methods for brucellosis are urgently needed, as China's urbanization and shifting consumer patterns are influencing the need for safer animal products.

In order to promote a comprehensive strategy for the prevention and control of brucellosis in the area, improved channels of communication and information sharing are also essential in bridging the gap between farmers and health authorities.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**China Brucellosis Market Drivers**

**Rising Incidence of Brucellosis in Livestock**

In China, the increasing prevalence of brucellosis among livestock is a prominent driver for the China [Brucellosis Market](../../../reports/brucellosis-market-5159). According to reports from the Ministry of Agriculture and Rural Affairs, China's livestock population has faced notable increases in brucellosis outbreaks, especially in regions such as Inner Mongolia and Xinjiang.

The frequency of livestock infection has been estimated to grow at an annual rate of 12%, which has a direct correlation to the rising demand for diagnostic tests and vaccines used in the prevention of the disease.

According to the Chinese Veterinary Medical Association, the control of brucellosis in livestock is critical for both public health and agricultural productivity, which in turn encourages investments and innovations in the brucellosis treatment market.

This increasing concern among governmental organizations and the agricultural sector will ultimately drive growth in the China Brucellosis Market, leading to enhanced product offerings and improved management strategies.

**Government Initiatives for Disease Control**

The Chinese government's proactive initiatives to control brucellosis outbreaks serve as a significant driver for the China Brucellosis Market. The State Council of China has implemented strict regulations and guidelines aimed at reducing incidences of brucellosis through awareness campaigns and legislation focused on prevention.

In recent years, the government has allocated increased funding for Research and Development of brucellosis control measures, rising by approximately 15% annually.

As a result, these initiatives facilitate the growth of pharmaceutical companies that develop vaccines and diagnostic tools specifically targeting brucellosis, aligning with the national health agendas. The response from governmental bodies and the consequent rise in funding play a vital role in shaping the dynamics of the China Brucellosis Market.

**Growing Awareness Among Farmers and Consumers**

The growing awareness of brucellosis among both farmers and consumers in China represents a crucial driver influencing the China Brucellosis Market.

Educational programs supported by the Ministry of Agriculture are increasingly reaching rural communities, where farmers are being equipped with knowledge about disease prevention and control strategies, notably in regions that have historically faced high infection rates.

Recent surveys indicated that approximately 70% of farmers in endemic regions now recognize the health benefits associated with vaccination and regular testing. This heightened awareness is not only leading to higher vaccine uptake but also enhancing diagnostic order volumes, ultimately driving the demand for brucellosis management solutions within the market.

**Technological Advancements in Diagnostics**

Technological advancements in diagnostic testing for brucellosis are driving growth in the China Brucellosis Market. Innovations, such as the development of rapid testing kits that deliver results within hours, have emerged from collaborations with esteemed research institutions in China like the Chinese Academy of Agricultural Sciences.

These advancements have led to a significant reduction in time and resources needed for disease confirmation, with adoption rates for these technologies estimated to rise by over 20% in the next five years.

Enhanced diagnostic capabilities enable quicker responses to outbreaks, fostering improvement in overall herd health management, and subsequently bolster the market for brucellosis-related products in China.

**China Brucellosis Market Segment Insights**

**Brucellosis Market species Insights**

The China Brucellosis Market is intricately segmented by species, with Brucella suis, B. abortus, and B. melitensis playing significant roles in the dynamics of the market. Brucella suis, often associated with swine, is particularly concerning for both agricultural health and food safety, given China's substantial pig farming industry.

Its prevalence in domestic animals poses a notable risk for zoonotic transmission to humans, thereby impacting public health initiatives and surveillance measures. B. abortus primarily impacts cattle and is crucial for the dairy industry, which is vital in China’s agricultural economy; managing this species is essential to secure both animal health and produce quality.

B. melitensis is highly pathogenic and is primarily associated with sheep and goats, making it a focal point in regions with a robust livestock sector, as it can lead to significant economic losses through livestock morbidity.

The collective focus on these species highlights their importance within the market, as controlling their prevalence is necessary for maintaining livestock health and ensuring the safety of the food supply chain. The demand for advanced diagnostics and vaccines continues to grow, driven by increasing concerns over Brucellosis outbreaks in livestock.

Enhanced surveillance and management strategies become fundamental, particularly as urbanization and agricultural practices evolve. With the increasing emphasis on agricultural biosecurity and public health in China, the insights into these species become crucial for fostering better health outcomes in both animals and humans.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**China Brucellosis Market Key Players and Competitive Insights**

The competitive landscape of the China Brucellosis Market reflects a complex interplay between various manufacturers and service providers focused on tackling the growing prevalence of brucellosis in livestock and its implications for public health.

This market is characterized by a burgeoning demand for vaccines, diagnostic kits, and effective treatment options aimed at reducing infection rates among livestock such as cattle, goats, and sheep. The Chinese government has put efforts into tackling this zoonotic disease through policy initiatives and funding for research and development.

Competitive insights reveal key players who are not only innovating in vaccine technology but also enhancing their production capabilities to meet both domestic and international market needs. Awareness campaigns and increased veterinary outreach programs significantly contribute to the market dynamics, thereby shaping competitive strategies among companies.

In the context of the China Brucellosis Market, the China Animal Husbandry Industry Company has established a stronghold with its comprehensive portfolio of veterinary vaccines and diagnostic solutions. This company's strengths lie in its extensive R&D capabilities and its commitment to producing high-quality, effective products specifically designed to combat brucellosis in livestock.

With a widespread distribution network and strategic partnerships with local veterinary services, the China Animal Husbandry Industry Company has successfully penetrated various regions across China, resulting in a robust presence in the market.

Their focus on educating farmers about brucellosis management further bolsters their reputation and reinforces customer loyalty, paving the way for future growth and innovation in the sector.

Xiamen Egens Biotechnology stands as a prominent player in the China Brucellosis Market, specializing in the development and commercialization of innovative testing kits and therapeutic agents. Known for its strong emphasis on biotechnology solutions, Xiamen Egens has carved a niche for itself by offering reliable and effective products that focus on early detection and prevention of brucellosis.

The company’s strengths are highlighted by its significant investment in R&D, resulting in advanced diagnostics that enhance animal health monitoring. Market presence is also reinforced through collaborations and strategic partnerships that allow Xiamen Egens to broaden its outreach and distribution channels across China.

The company has been active in merging and acquiring smaller biotech firms, which accelerates its innovation pipeline and expands its product offerings, ensuring that it remains competitive in the evolving landscape of animal health solutions focused on brucellosis.

**Key Companies in the China Brucellosis Market Include:**

- China Animal Husbandry Industry Company
- Xiamen Egens Biotechnology
- Guangzhou Liyuan Biotechnology
- Shenzhen Lianhe Biological Technology
- Beijing Wantai Biological Pharmacy
- Hengshui Shengxin Biological Pharmaceutical
- Wuhan Institute of Biological Products
- Jiangsu Kubo BioTechnology
- China National Pharmaceutical Group
- Zhejiang Kehua BioEngineering

**China Brucellosis****Market****Developments**

The China Brucellosis Market has seen noteworthy developments recently, particularly with a focus on controlling and managing brucellosis outbreaks, which have impacted both public health and the livestock industry. In recent months, the Ministry of Agriculture and Rural Affairs in China has emphasized the importance of vaccination and surveillance measures in livestock to mitigate the disease.

Companies such as China Animal Husbandry Industry Company and Beijing Wantai Biological Pharmacy are leading efforts in Research and Development for effective vaccines against Brucellosis.

Additionally, there has been notable growth in the market, enhancing valuations of firms like Xiamen Egens Biotechnology and Guangzhou Liyuan Biotechnology, attributed to rising awareness and regulatory support for disease management.

Furthermore, in July 2023, Shenzhen Lianhe Biological Technology announced an acquisition of certain assets from Jiangsu Kubo Biotechnology, indicating consolidation trends within the sector. This acquisition is aligned with the broader strategic goals to enhance capabilities in vaccine development and distribution.

Major incidents in the past few years have prompted regulatory mandates for improved biosecurity measures, influencing the operational landscape for firms like Hengshui Shengxin Biological Pharmaceutical and Wuhan Institute of Biological Products.

**China Brucellosis Market Segmentation Insights**

**Brucellosis Market species Outlook**

- Brucella suis
- B. abortus
- B. melitensis

## Market Drivers

### Rising Public Health Concerns

Rising public health concerns regarding zoonotic diseases, including brucellosis, are shaping the China brucellosis market. As awareness of the transmission of diseases from animals to humans increases, there is a growing emphasis on preventive measures. Public health campaigns have been launched to educate communities about the risks associated with brucellosis, particularly in regions with high livestock density. In 2025, surveys indicated that over 60% of the population in affected areas recognized brucellosis as a health threat. This heightened awareness is likely to drive demand for vaccines and diagnostic services, as individuals and healthcare providers seek to protect public health. The intersection of animal health and human health is becoming increasingly recognized, further propelling the market for brucellosis-related products and services.

### Rising Incidence of Brucellosis

The increasing incidence of brucellosis in China is a critical driver for the China brucellosis market. Reports indicate that the number of brucellosis cases has been on the rise, particularly in rural areas where livestock farming is prevalent. In 2025, the Ministry of Agriculture reported over 10,000 confirmed cases, highlighting the urgent need for effective management and control measures. This surge in cases has prompted both governmental and non-governmental organizations to prioritize brucellosis prevention and treatment, thereby driving demand for diagnostic tools and vaccines. The heightened awareness of the disease's impact on public health and livestock productivity further fuels the market, as stakeholders seek to mitigate risks associated with brucellosis outbreaks.

### Government Initiatives and Policies

Government initiatives aimed at controlling brucellosis outbreaks significantly influence the China brucellosis market. The Chinese government has implemented various policies to enhance disease surveillance, vaccination programs, and public health education. For instance, the National Brucellosis Control Program, launched in 2024, aims to reduce the incidence of the disease by 50% by 2030. This program includes funding for research and development of vaccines and diagnostic tests, which is expected to bolster the market. Additionally, local governments are incentivizing farmers to vaccinate their livestock, thereby increasing the demand for [brucellosis vaccines](https://www.marketresearchfuture.com/reports/brucellosis-vaccine-market-43217) and diagnostic services. These proactive measures indicate a strong commitment to addressing the brucellosis challenge in China.

### Increased Livestock Trade and Movement

The expansion of livestock trade and movement within China serves as a significant driver for the China brucellosis market. As the demand for meat and dairy products continues to grow, the movement of livestock between regions has increased, raising concerns about the spread of brucellosis. In 2025, the livestock sector contributed over 20% to China's agricultural GDP, underscoring its economic importance. However, this growth also poses challenges in disease control, as brucellosis can easily spread through infected animals. Consequently, there is a heightened focus on implementing stringent biosecurity measures and vaccination protocols to safeguard livestock health. This situation creates opportunities for diagnostic and vaccine manufacturers, as stakeholders seek to mitigate the risks associated with livestock trade.

### Technological Advancements in Diagnostics

Technological advancements in diagnostic methods are transforming the China brucellosis market. The introduction of rapid and accurate diagnostic tests has improved the ability to detect brucellosis in both humans and animals. Innovations such as polymerase chain reaction (PCR) tests and serological assays have gained traction among healthcare providers and veterinarians. In 2025, the market for brucellosis diagnostics in China was valued at approximately USD 50 million, reflecting a growing reliance on advanced technologies. These diagnostic tools not only facilitate early detection but also enhance the effectiveness of vaccination campaigns. As the demand for reliable diagnostic solutions continues to rise, the market is likely to experience substantial growth, driven by both public health needs and livestock management practices.

## Future Outlook

The China brucellosis market is projected to grow at a 6.28% CAGR from 2025 to 2035, driven by increased livestock health awareness and advancements in diagnostic technologies.

**New opportunities:**

- Development of mobile diagnostic units for rural areas
- Investment in vaccine production facilities to meet rising demand
- Partnerships with agricultural cooperatives for awareness campaigns

By 2035, the market is expected to achieve robust growth, positioning itself as a leader in livestock disease management.

## Segment Insights

### By Species: Brucella melitensis (Largest) vs. Brucella suis (Fastest-Growing)

In the China brucellosis market, the distribution of market share among the various Brucella species reveals that Brucella melitensis holds the largest share, being predominantly recognized in both livestock and human cases. Following closely, Brucella suis is gaining traction, suggesting a shift in focus towards this strain due to its increasing prevalence in specific animal populations and its impact on zoonotic diseases.

The growth trends within this segment are significantly influenced by rising awareness and the need for effective brucellosis management in livestock. The demand for vaccines and diagnostic tests targeted at Brucella suis has been accelerating, marking it as the fastest-growing segment. Factors such as increased agricultural activities, changing regulations, and heightened public health campaigns are further driving this growth.

Brucella melitensis (Dominant) vs. Brucella suis (Emerging)

Brucella melitensis is currently the dominant species in the market, characterized by its strong historical presence and recognition as a primary causative agent of brucellosis in humans. Its significant impact on livestock, particularly goats and sheep, has created a substantial demand for effective control measures. Conversely, Brucella suis is emerging rapidly, recognized for its role in causing brucellosis in pigs. This species is becoming increasingly relevant, especially in regions where pork production is on the rise. The dynamic between these two species highlights a shift in focus, with rising investments in research and development to handle the unique challenges each strain presents to animal health and public safety.

### By Diagnosis: Serological Tests (Largest) vs. Molecular Techniques (Fastest-Growing)

The diagnosis segment of the China brucellosis market is notably diverse, with serological tests holding the largest share due to their widespread application and established reliability. Other techniques, such as molecular methods, are emerging rapidly, as they offer higher accuracy and quicker results, contributing significantly to the market dynamics. Bone marrow biopsies, while essential, occupy a smaller niche, and advanced imaging techniques such as X-rays and CT scans complement these diagnostic approaches, enhancing overall diagnostic efficacy.

Growth trends indicate a marked increase in the adoption of molecular techniques, fueled by technological advancements and a growing emphasis on early detection of brucellosis. This shift is driven by healthcare providers' recognition of the benefits of rapid diagnostics and improved patient outcomes. Additionally, rising awareness about brucellosis and its implications on public health is propelling investments in diagnostic technologies, paving the way for innovative solutions that shape the future of this segment in the market.

Serological Tests (Dominant) vs. Molecular Techniques (Emerging)

Serological tests are dominant in the diagnosis segment, providing reliable results for brucellosis detection through antibody identification, thus widely utilized across healthcare facilities. Their established methodology and accessibility make them a staple in clinical settings. In contrast, molecular techniques are gaining traction as an emerging value, utilizing advanced capabilities to detect the brucella DNA, thereby reducing time-to-diagnosis significantly. This advantage positions molecular methods as a preferred choice in critical care and research environments, indicating a shifting landscape towards precision diagnostics in the China brucellosis market.

### By Treatment: Antibiotics (Largest) vs. Vaccines (Fastest-Growing)

In the China brucellosis market, the treatment segment is primarily composed of antibiotics, vaccines, and other therapeutic agents. Antibiotics hold the largest market share due to their established efficacy in treating brucellosis, significantly contributing to the overall market dynamics. They are widely prescribed by healthcare professionals and have been the cornerstone of brucellosis treatment protocols. Conversely, vaccines are witnessing rapid growth, fueled by increasing awareness of preventative care and the rising incidence of brucellosis cases in livestock and humans.

The growth trends within this segment are influenced by advancements in pharmaceutical research and development, along with heightened governmental and regulatory support for vaccination programs. Factors such as rising demand for brucellosis control and management, coupled with emerging technologies in vaccine development, are propelling the vaccines segment to new heights. Moreover, the increasing focus on animal health and welfare further underscores the importance of both antibiotics and vaccines, with the latter gaining traction as a proactive measure against brucellosis outbreaks.

Antibiotics (Dominant) vs. Vaccines (Emerging)

Antibiotics are the dominant force in the treatment segment, mainly credited to their widespread use in managing brucellosis infections. Their formulation is well-established, allowing for effective treatment of infected individuals and animals. The prescription of antibiotics is supported by a variety of clinical studies demonstrating their success in curbing the disease. On the other hand, vaccines represent an emerging yet crucial segment. The electrifying pace of research is leading to innovative vaccine formulations, enhancing their appeal as preventive solutions. The vaccines are becoming increasingly essential, especially in rural areas where brucellosis prevalence is high among livestock. Overall, while antibiotics remain the mainstay for treatment, vaccines are carving out a significant and growing niche in the market.

### By End-User: Hospitals & Diagnostic Centers (Largest) vs. Pharmaceutical & Biotechnology Companies (Fastest-Growing)

The distribution of market share in the End-User segment is primarily led by hospitals and diagnostic centers, which cater to the immediate healthcare needs and testing services for brucellosis. These centers' crucial role in diagnosing and managing brucellosis directly places them at the forefront of the market. Following closely, pharmaceutical and biotechnology companies are emerging as significant players, particularly in the development of innovative diagnostics and treatments, which is vital given the rising prevalence of outbreaks.

Growth trends are largely driven by an increasing awareness of brucellosis's impact on public health among hospitals and diagnostic centers. There is a notable surge in investments directed towards research and development within pharmaceutical and biotechnology companies, which are rapidly adopting advanced technologies to improve testing and treatment. Moreover, public health initiatives aimed at eradicating brucellosis are expanding, thereby encouraging a robust collaborative approach between diagnostic centers and biotechnology firms.

Hospitals & Diagnostic Centers (Dominant) vs. Pharmaceutical & Biotechnology Companies (Emerging)

Hospitals and diagnostic centers play a dominant role in the End-User segment, primarily due to their extensive resources and established infrastructure for testing and treating infectious diseases like brucellosis. Their comprehensive services range from initial diagnosis to extensive treatment plans, positioning them as key players in combating the disease. Conversely, pharmaceutical and biotechnology companies represent the emerging force in this market, harnessing cutting-edge technologies to develop novel diagnostic tools and therapeutics. This segment is gaining momentum, driven by innovations that enhance treatment efficacy and patient outcomes. The collaboration between diagnostic centers and biotech firms is crucial, paving the way for advancements that could lead to better management and control of brucellosis.

## Competitive Benchmarking

The competitive dynamics within the brucellosis market in China are characterized by a blend of innovation, strategic partnerships, and regional expansion. Key players such as China National Pharmaceutical Group Corporation (CN), Hubei Huanong Animal Health Products Co Ltd (CN), and Zhejiang Sijiqing Animal Pharmaceutical Co Ltd (CN) are actively shaping the landscape. China National Pharmaceutical Group Corporation (CN) appears to be focusing on enhancing its research and development capabilities, which may bolster its product offerings and market share. Meanwhile, Hubei Huanong Animal Health Products Co Ltd (CN) is likely concentrating on localizing its manufacturing processes to improve supply chain efficiency, thereby reducing costs and enhancing responsiveness to market demands. Collectively, these strategies suggest a competitive environment that is moderately fragmented, with companies vying for market leadership through innovation and operational excellence.

In terms of business tactics, localizing manufacturing and optimizing supply chains are pivotal strategies employed by these companies. The market structure is moderately fragmented, with several players competing for market share. The collective influence of these key players indicates a dynamic environment where agility and responsiveness to market changes are crucial for success. Companies are increasingly focusing on enhancing their operational efficiencies to maintain a competitive edge.

In December 2025, China National Pharmaceutical Group Corporation (CN) announced a strategic partnership with a leading biotechnology firm to develop advanced vaccines for brucellosis. This collaboration is expected to leverage cutting-edge research and technology, potentially leading to more effective solutions in combating the disease. The strategic importance of this partnership lies in its potential to enhance the company's product portfolio and strengthen its position in the market.

In November 2025, Hubei Huanong Animal Health Products Co Ltd (CN) launched a new line of brucellosis diagnostic kits aimed at improving early detection in livestock. This initiative reflects the company's commitment to innovation and addresses the growing demand for rapid and accurate diagnostic solutions. The introduction of these kits may significantly impact disease management practices within the agricultural sector, thereby enhancing the company's market presence.

In October 2025, Zhejiang Sijiqing Animal Pharmaceutical Co Ltd (CN) expanded its distribution network by entering into agreements with regional distributors across several provinces. This strategic move is likely to enhance the company's market reach and improve accessibility to its products. By strengthening its distribution capabilities, the company may better serve the needs of local farmers and veterinarians, thereby solidifying its competitive position.

As of January 2026, current trends in the brucellosis market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in product development and [supply chain management](https://www.marketresearchfuture.com/reports/supply-chain-management-market-21742). Strategic alliances are playing a crucial role in shaping the competitive landscape, as companies seek to pool resources and expertise to drive innovation. Looking ahead, it appears that competitive differentiation will evolve from traditional price-based competition to a focus on technological advancements, innovative solutions, and reliable supply chains. This shift may ultimately redefine how companies position themselves in the market, emphasizing the importance of adaptability and forward-thinking strategies.

## Recent News & Developments

The China Brucellosis Market has seen noteworthy developments recently, particularly with a focus on controlling and managing brucellosis outbreaks, which have impacted both public health and the livestock industry. In recent months, the Ministry of Agriculture and Rural Affairs in China has emphasized the importance of vaccination and surveillance measures in livestock to mitigate the disease.

Companies such as China Animal Husbandry Industry Company and Beijing Wantai Biological Pharmacy are leading efforts in Research and Development for effective vaccines against Brucellosis.

Additionally, there has been notable growth in the market, enhancing valuations of firms like Xiamen Egens Biotechnology and Guangzhou Liyuan Biotechnology, attributed to rising awareness and regulatory support for disease management.

Furthermore, in July 2023, Shenzhen Lianhe Biological Technology announced an acquisition of certain assets from Jiangsu Kubo Biotechnology, indicating consolidation trends within the sector. This acquisition is aligned with the broader strategic goals to enhance capabilities in vaccine development and distribution.

Major incidents in the past few years have prompted regulatory mandates for improved biosecurity measures, influencing the operational landscape for firms like Hengshui Shengxin Biological Pharmaceutical and Wuhan Institute of Biological Products.

## Report Scope

| MARKET SIZE 2024 | 49.32(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 53.3(USD Million) |
| MARKET SIZE 2035 | 96.38(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.28% (2024 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | China Animal Health and Epidemiology Center (CN), China National Pharmaceutical Group Corporation (CN), Hubei Huanong Animal Health Products Co Ltd (CN), Zhejiang Sijiqing Animal Pharmaceutical Co Ltd (CN), Shenzhen Huitong Pharmaceutical Co Ltd (CN), Guangdong Huanan Animal Health Products Co Ltd (CN), Beijing Huaduo Animal Health Technology Co Ltd (CN), Jiangsu Yurun Group Co Ltd (CN) |
| Segments Covered | Application, End Use, Distribution Channel, Product Type |
| Key Market Opportunities | Increasing demand for advanced diagnostic tools and vaccines in the china brucellosis market. |
| Key Market Dynamics | Rising regulatory scrutiny and technological advancements are reshaping the competitive landscape of China's brucellosis market. |
| Countries Covered | China |

## Frequently Asked Questions

**Q: What is the current valuation of the China brucellosis market in 2024?**
A: The overall market valuation was $59.18 Million in 2024.

**Q: What is the projected market size for the China brucellosis market by 2035?**
A: The projected valuation for 2035 is $124.2 Million.

**Q: What is the expected CAGR for the China brucellosis market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during this period is 6.97%.

**Q: Which companies are the key players in the China brucellosis market?**
A: Key players include Zoetis Inc, Merck & Co Inc, Boehringer Ingelheim GmbH, and others.

**Q: What are the main species segments in the China brucellosis market?**
A: Main species segments include Brucella abortus, Brucella melitensis, and Brucella suis.

**Q: What is the market valuation for Brucella melitensis in 2024?**
A: The market valuation for Brucella melitensis was $20.0 Million in 2024.

**Q: How much is expected to be spent on antibiotics in the treatment segment by 2035?**
A: Spending on antibiotics in the treatment segment is expected to reach $40.0 Million by 2035.

**Q: What is the projected market size for serological tests in the diagnosis segment by 2035?**
A: The projected market size for serological tests in the diagnosis segment is $20.0 Million by 2035.

**Q: What is the expected market size for hospitals and diagnostic centers as end-users by 2035?**
A: The expected market size for hospitals and diagnostic centers as end-users is $40.0 Million by 2035.

**Q: What is the anticipated growth in the vaccines segment for treatment by 2035?**
A: The anticipated growth in the vaccines segment for treatment is expected to reach $50.0 Million by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/china-brucellosis-market-53597*